- ASSISTANT PROFESSOR Medicine, Nephrology
MD, University of Connecticut
Residency, Internal Medicine
Yale-New Haven Hospital
Mount Sinai Hospital
Kidney podocytes are the target cells for injury in human glomerular disease, a significant cause of end stage kidney failure. Primary and secondary pathogenic processes affecting podocytes account for 90% of end-stage kidney disease at a cost of 20 billion dollars per year in the US. A reduction in podocyte number (podocytopenia) directly correlates with the progression of several proteinuric kidney diseases including focal segmental glomerulosclerosis (FSGS), IgA nephropathy and diabetic nephropathy. Despite significant advances in the characterization of the molecular architecture of podocytes, the mechanisms underlying their survival, injury and loss remain poorly understood. Validated therapeutic targets are scarce and there are currently no podocyte-specific drugs commercially available. The overall goal of our research program is to enhance the pipeline of putative therapeutic targets available to tackle human glomerular disease by elucidating the details and functional significance of key signaling pathways that regulate podocyte injury and survival. We utilize cell-based assays and rodent models to identify and characterize key mediators of glomerular disease progression.
Asanuma K, Campbell KN, Kim K, Faul C, Mundel P. Nuclear relocation of the nephrin and CD2AP-binding protein dendrin promotes apoptosis of podocytes. Proceedings of the National Academy of Sciences of the United States of America 2007 Jun; 104(24).
Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, Chang JM, Choi HY, Campbell KN, Kim K, Reiser J, Mundel P. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nature medicine 2008 Sep; 14(9).
Sieber J, Lindenmeyer MT, Kampe K, Campbell KN, Cohen CD, Hopfer H, Mundel P, Jehle AW. Regulation of podocyte survival and endoplasmic reticulum stress by fatty acids. American journal of physiology. Renal physiology 2010 Oct; 299(4).
Campbell KN, Raij L, Mundel P. Role of angiotensin II in the development of nephropathy and podocytopathy of diabetes. Current diabetes reviews 2011 Jan; 7(1).
Campbell KN, Wong JS, Gupta R, Asanuma K, Sudol M, He JC, Mundel P. Yes-associated protein (YAP) promotes cell survival by inhibiting proapoptotic dendrin signaling. The Journal of biological chemistry 2013 Jun; 288(24).
Yu CC, Fornoni A, Weins A, Hakroush S, Maiguel D, Sageshima J, Chen L, Ciancio G, Faridi MH, Behr D, Campbell KN, Chang JM, Chen HC, Oh J, Faul C, Arnaout MA, Fiorina P, Gupta V, Greka A, Burke GW, Mundel P. Abatacept in B7-1-positive proteinuric kidney disease. The New England journal of medicine 2013 Dec; 369(25).
Potla U, Ni J, Vadaparampil J, Yang G, Leventhal JS, Campbell KN, Chuang PY, Morozov A, He JC, D'Agati VD, Klotman PE, Kaufman L. Podocyte-specific RAP1GAP expression contributes to focal segmental glomerulosclerosis-associated glomerular injury. The Journal of clinical investigation 2014 Apr; 124(4).
Campbell KN, He JC. Can biomarkers of disease activity guide treatment in FSGS?. Clinical journal of the American Society of Nephrology : CJASN 2014 Sep; 9(9).
Yacoub R, Campbell KN. Inhibition of RAS in diabetic nephropathy. International journal of nephrology and renovascular disease 2015; 8.
Schwartzman M, Reginensi A, Wong JS, Basgen JM, Meliambro K, Nicholas SB, D'Agati V, McNeill H, Campbell KN. Podocyte-Specific Deletion of Yes-Associated Protein Causes FSGS and Progressive Renal Failure. Journal of the American Society of Nephrology : JASN 2015 May;.
Weins A, Wong JS, Basgen JM, Gupta R, Daehn I, Casagrande L, Lessman D, Schwartzman M, Meliambro K, Patrakka J, Shaw A, Tryggvason K, He JC, Nicholas SB, Mundel P, Campbell KN. Dendrin ablation prolongs life span by delaying kidney failure. The American journal of pathology 2015 Aug; 185(8).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Campbell during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- Keryx Biopharmaceuticals, Inc.
Scientific Advisory Board:
- Questcor Pharmaceuticals, Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Annenberg Building Floor 23 Room 04C
1468 Madison Avenue
New York, NY 10029